增强CT检查纹理分析对胃癌Claudin 18.2表达状态的预测价值

Predictive value of enhanced CT texture analysis for Claudin 18.2 expression in gastric cancer

  • 摘要:
    目的 探讨增强CT检查纹理分析对胃癌Claudin 18.2表达状态的预测价值。
    方法 采用回顾性队列研究方法。收集2023年1月至2025年10月江苏省人民医院和南京医科大学附属明基医院收治的196例胃癌患者临床病理资料;男112例,女84例;年龄为(59±12)岁。患者通过随机数字表法按7∶3分为训练集(137例)和验证集(59例)。训练集用于构建预测模型,验证集用于验证预测模型。患者术前均行腹部增强CT检查,并行胃癌根治性手术或胃镜检查获取标本。观察指标:(1)Claudin 18.2表达情况及临床病理特征比较。(2)纹理特征筛选结果。(3)预测模型的构建及效能评估。正态分布的计量资料组间比较采用独立样本t检验;偏态分布的计量资料组间比较采用Mann‑Whitney U检验。计数资料组间比较采用χ²检验。等级资料组间比较采用Mann‑Whitney U秩和检验。采用组内相关指数(ICC)进行一致性检验,ICC>0.75为一致性良好。绘制受试者工作特征(ROC)曲线,以曲线下面积(AUC)、校准曲线、决策曲线评估各模型预测效能。采用Delong检验比较AUC。
    结果 (1) Claudin 18.2表达情况及临床病理特征比较:196例胃癌患者中,Claudin 18.2阳性63例,阴性133例。训练集和验证集中阳性分别为43例和20例,两组阳性比例比较,差异无统计学意义(χ²=0.12,P>0.05)。训练集胃癌Claudin 18.2阳性患者Lauren分型为肠型、弥漫型、混合型分别为10、21、12例,阴性患者分别为36、25、33例;Claudin 18.2阳性患者肿瘤分化程度为高分化、中分化、低分化分别为5、8、30例,阴性患者分别为15、41、38例;两类患者上述指标比较,差异均有统计学意义(χ²=6.80,Z=-2.80,P<0.05)。(2)纹理特征筛选结果:提取增强CT检查静脉期和动脉期共156项纹理特征,其中观察者间及观察者内ICC>0.75的纹理特征132项。将132项纹理特征纳入最小绝对收缩与选择算子算法回归分析进一步筛选出9个与Claudin 18.2表达相关的关键纹理特征,其中动脉期5项,静脉期4项,特征系数非零且稳定性良好。(3)预测模型的构建及效能评估:根据临床特征和CT检查影像学特征,构建临床预测模型、CT检查纹理特征预测模型、联合预测模型。训练集中临床预测模型、CT检查纹理特征预测模型、联合预测模型的AUC分别为0.6995%可信区间(CI)为0.60~0.76、0.89(95%CI为0.83~0.94)、0.90(95%CI为0.84~0.94);验证集中3种预测模型AUC分别为0.71(95%CI为0.61~0.87)、0.88(95%CI为0.77~0.96)、0.89(95%CI为0.78~0.96)。Delong检验结果显示:训练集联合预测模型和CT检查纹理特征预测模型的AUC均高于临床预测模型(Z=4.56,3.82,P<0.05)。校准曲线分析结果显示:联合预测模型校准效能良好。决策曲线分析结果显示:联合预测模型具备临床应用价值。
    结论 基于增强CT检查纹理分析可有效预测胃癌Claudin 18.2表达状态,且与临床病理学特征构建的联合预测模型效能优于单一模型。

     

    Abstract:
    Objective To investigate the predictive value of enhanced computed tomography (CT) texture analysis for Claudin 18.2 expression in gastric cancer.
    Methods The retrospective cohort study was conducted. The clinicopathological data of 196 patients with gastric cancer who were admitted to Jiangsu Province Hospital and Nanjing BenQ Medical Center of Nanjing Medical University from January 2023 to October 2025 were collected. There were 112 males and 84 females, aged (59±12) years. Patients were randomly divided into a training set (137 cases) and a validation set (59 cases) at a ratio of 7∶3 using the random number table method. The training set was used to construct the predictive model, and the validation set was used to validate the predictive model. All patients underwent preoperative abdominal enhanced CT examination, and received radical gastrectomy or gastroscopy to obtain specimens. Observation indicators: (1) Claudin 18.2 expression and comparison of clinicopathological characteristics; (2) results of texture feature screening; (3) construction and efficacy evaluation of the predictive model. Comparison of measurement data with normal distribution between groups was conducted using the independent sample t test. Comparison of measurement data with skewed distribution between groups was conducted using the Mann‑Whitney U test. Comparison of count data between groups was conducted using the chi‑square test. Comparison of ordinal data between groups was conducted using the Mann-Whitney rank sum test. Intraclass correlation coefficient (ICC) was used for consistency test, and ICC >0.75 indicated good consistency. Receiver operating characteristic (ROC) curves were plotted, and the area under the curve (AUC), calibration curve, and decision curve were used to evaluate the predictive efficacy of each model. DeLong test was used to compare the AUC.
    Results (1) Claudin 18.2 expression and comparison of clinicopathological characteristics: among 196 gastric cancer patients, 63 cases were Claudin 18.2 positive and 133 cases were negative. There were 43 and 20 positive cases in the training and validation sets respectively, with no significant difference in the positive proportion between the two groups (χ²=0.12, P>0.05). In the training set, cases with Lauren classification as intestinal type, diffuse type, and mixed type were 10, 21, and 12 for Claudin 18.2 expression positive gastric cancer patients, versus 36, 25, and 33 for Claudin 18.2 expression negative gastric cancer patients. Cases with well‑differentiated, moderately differentiated, and poorly differentiated tumor were 5, 8, and 30 for Claudin 18.2 positive gastric cancer patients, versus 15, 41, and 38 for Claudin 18.2 negative gastric cancer patients. There were significant differences in the above indicators between them (χ²=6.80, Z=-2.80, P<0.05). (2) Results of texture feature screening: a total of 156 texture features were extracted from the arterial and venous phases of enhanced CT examination. Among them, 132 texture features with inter‑observer and intra‑observer ICC >0.75 were included in least absolute shrinkage and selection operator regression analysis for further screening. Nine key texture features associated with Claudin 18.2 expression were identified, including 5 from the arterial phase and 4 from the venous phase, with non‑zero feature coefficients and good stability. (3) Construction and efficacy evaluation of the predictive model: based on clinical characteristics and CT imaging features, a clinical prediction model, a CT texture feature prediction model, and a combined prediction model were constructed. In the training set, the AUCs of the clinical prediction model, CT texture feature prediction model, and combined prediction model were 0.69 95% confidence interval (CI) as 0.60-0.76, 0.89 (95%CI as 0.83-0.94), and 0.90 (95%CI as 0.84-0.94), respectively. In the validation set, the AUCs of the prediction three models were 0.71 (95%CI as 0.61-0.87), 0.88 (95%CI as 0.77-0.96), and 0.89 (95%CI as 0.78-0.96), respectively. The results of DeLong test showed that in the training set, the AUCs of the combined prediction model and the CT texture feature prediction model were both higher than that of the clinical prediction model (Z=4.56, 3.82, P<0.05). The results of calibration curve analysis showed a good calibration performance in the combined prediction model. The results of decision curve analysis showed clinical application value in the combined prediction model.
    Conclusion Eenhanced CT‑based texture analysis can effectively predict Claudin 18.2 expression status in gastric cancer, and the combined prediction model incorporating clinicopathological characteristics has better predictive efficacy than single models.

     

/

返回文章
返回